These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 24913320

  • 21. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.
    Elsamman EM, Fukumori T, Tanimoto S, Nakanishi R, Takahashi M, Toida K, Kanayama HO.
    BJU Int; 2006 Sep; 98(3):668-73. PubMed ID: 16925770
    [Abstract] [Full Text] [Related]

  • 22. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
    Du P, Ye L, Yang Y, Jiang WG.
    Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
    [Abstract] [Full Text] [Related]

  • 23. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M, Kimura F, Kagata Y, Kondoh N, Asano T, Yamamoto M, Hayakawa M.
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [Abstract] [Full Text] [Related]

  • 24. RCCRT1 is correlated with prognosis and promotes cell migration and invasion in renal cell carcinoma.
    Song S, Wu Z, Wang C, Liu B, Ye X, Chen J, Yang Q, Ye H, Xu B, Wang L.
    Urology; 2014 Sep; 84(3):730.e1-7. PubMed ID: 25168566
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
    Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X.
    Clin Cancer Res; 2014 May 15; 20(10):2617-30. PubMed ID: 24647573
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.
    Chen D, Gassenmaier M, Maruschke M, Riesenberg R, Pohla H, Stief CG, Zimmermann W, Buchner A.
    J Urol; 2014 Feb 15; 191(2):479-86. PubMed ID: 24012533
    [Abstract] [Full Text] [Related]

  • 30. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V, Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project, Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.
    BJU Int; 2012 Jul 15; 110(1):76-83. PubMed ID: 22044519
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.
    Tang J, Wang F, Cheng G, Si S, Sun X, Han J, Yu H, Zhang W, Lv Q, Wei JF, Yang H.
    J Exp Clin Cancer Res; 2018 Feb 27; 37(1):40. PubMed ID: 29482572
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H, Huang B, Wang H, Liu X, Hong Y, Qiu S, Zheng J.
    Cell Physiol Biochem; 2018 Feb 27; 51(2):991-1000. PubMed ID: 30466107
    [Abstract] [Full Text] [Related]

  • 36. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
    Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH.
    Oncol Rep; 2011 Jan 27; 25(1):129-33. PubMed ID: 21109967
    [Abstract] [Full Text] [Related]

  • 37. GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma.
    Xue Y, Wu G, Liao Y, Xiao G, Ma X, Zou X, Zhang G, Xiao R, Wang X, Liu Q, Long D, Yang J, Xu H, Liu F, Liu M, Xie K, Huang R.
    Br J Cancer; 2014 Apr 29; 110(9):2250-60. PubMed ID: 24595000
    [Abstract] [Full Text] [Related]

  • 38. TRIM59 is a key regulator of growth and migration inrenal cell carcinoma.
    Hu SH, Zhao MJ, Wang WX, Xu CW, Wang GD.
    Cell Mol Biol (Noisy-le-grand); 2017 May 20; 63(5):68-74. PubMed ID: 28719348
    [Abstract] [Full Text] [Related]

  • 39. Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
    Wei R, He D, Zhang X.
    Cell Physiol Biochem; 2018 May 20; 49(6):2348-2357. PubMed ID: 30261494
    [Abstract] [Full Text] [Related]

  • 40. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
    Sandlund J, Ljungberg B, Wikström P, Grankvist K, Lindh G, Rasmuson T.
    Acta Oncol; 2009 May 20; 48(6):909-14. PubMed ID: 19322701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.